1. Real-World Analysis of the Efficacy and Safety of a Novel Irreversible HER2 Tyrosine Kinase Inhibitor Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer
   Ying Sun et al, 2021, Cancer Management and Research CrossRef
2. Pyrotinib: A promising therapeutic prospect for treating metastatic salivary gland cancer
   Dhanraj Ganapathy et al, 2024, Oral Oncology Reports CrossRef
3. Effect of Fluconazole on the Pharmacokinetics of Pyrotinib Maleate: A Single-Center, Open, Single-Dose, Self-Controlled Study in Healthy Chinese Participants
   Yuanming Song et al, 2023, Journal of Clinical Pharmacy and Therapeutics CrossRef
4. New thiazole-based derivatives as EGFR/HER2 and DHFR inhibitors: Synthesis, molecular modeling simulations and anticancer activity
   Mohamed A. Sabry et al, 2022, European Journal of Medicinal Chemistry CrossRef
5. Pyrotinib Treatment in Patients With HER2-positive Metastatic Breast Cancer and Brain Metastasis: Exploratory Final Analysis of Real-World, Multicenter Data
   Munawar Anwar et al, 2021, Clinical Cancer Research CrossRef
6. Differential effects of ketoconazole, fluconazole, and itraconazole on the pharmacokinetics of pyrotinib in vitro and in vivo
   Li Wang et al, 2022, Frontiers in Pharmacology CrossRef
7. Combined trastuzumab and radiation therapy for HER2-positive uterine serous carcinoma: A case report
   SPH Mao et al, 2023, Gynecologic Oncology Reports CrossRef
8. Combination of radiotherapy and targeted therapy for HER2-positive breast cancer brain metastases
   Xiaojing Yang et al, 2023, European Journal of Medical Research CrossRef
9. Case Report: Durable Clinical Response to Third-Line Pyrotinib After Resistance to Trastuzumab in a Gastric Cancer Patient
   Junyi Wu et al, 2022, Frontiers in Oncology CrossRef
10. Pyrotinib combining with radiotherapy on breast cancer with brain metastasis
    Xiaoping Ma et al, 2023, Experimental Biology and Medicine CrossRef
11. Effects of rifampicin on antineoplastic drug pyrotinib maleate pharmacokinetics in healthy subjects
    Ming-min Cai et al, 2022, Investigational New Drugs CrossRef
12. Pyrotinib-based treatments in HER2-positive breast cancer patients with brain metastases
    Xiaoping Ma et al, 2022, Annals of Medicine CrossRef
13. Pyrotinib and Trastuzumab Plus Chemotherapy Serve as an Acceptable Neoadjuvant Regimen Exhibiting Good Efficacy and Tolerance in HER2-Positive Breast Cancer Patients
    Yibo Chen et al, 2024, Cancer Biotherapy and Radiopharmaceuticals CrossRef
14. A review of therapeutic agents for breast cancer with potentially radiosensitizing properties
    Zhongwei Zhang et al, 2024, Radiation Medicine and Protection CrossRef
15. HER2-positive advanced biliary tract cancer responds to second-line pyrotinib therapy: a case report
    Linger Liu et al, 2024, Anti-Cancer Drugs CrossRef
16. Molecular mechanisms of chemo‐ and radiotherapy resistance and the potential implications for cancer treatment
    Ya‐Ping Liu et al, 2021, MedComm CrossRef
17. Molecular perspective on targeted therapy in breast cancer: a review of current status
    Busra Demir Cetinkaya et al, 2022, Medical Oncology CrossRef
18. Real-World Study: A Powerful Tool for Malignant Tumor Research in General Surgery
    Liang Zhang et al, 2022, Cancers CrossRef
19. Sustained Clinical Benefit of Pyrotinib Combined with Capecitabine Rescue Therapy After Trastuzumab Resistance in HER2-Positive Advanced Gastric Cancer: A Case Report
    Xin Li et al, 2021, OncoTargets and Therapy CrossRef
20. Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer
    Giulia Petroni et al, 2022, Nature Reviews Clinical Oncology CrossRef
21. Pyrotinib Targeted EGFR-STAT3/CD24 Loop-Mediated Cell Viability in TSC
    Xiao Han et al, 2022, Cells CrossRef
22. Ginsenoside Rg3 enhances the radiosensitivity of lung cancer A549 and H1299 cells via the PI3K/AKT signaling pathway
    Jialin Li et al, 2023, In Vitro Cellular & Developmental Biology - Animal CrossRef
23. Effectiveness and safety of pyrotinib-based therapy in the treatment of HER2-positive breast cancer patients with brain metastases: a multicenter real-world study
    Jie Huang et al, 2024, Clinical Breast Cancer CrossRef
24. High Expression of PKMYT1 Predicts Poor Prognosis and Aggravates the Progression of Osteosarcoma via the NF-κB Pathway in MG63 Cells
    Yang Lu et al, 2023, Current Cancer Drug Targets CrossRef